TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Theravance Stock Declines Around 17% in Three Months: Here's Why
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
Theravance's Q4 Earnings and Revenues Miss Estimates
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $22.60 Consensus PT from Brokerages
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study
Theravance Biopharma Plummets As Phase 3 Study Falls Short
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
Theravance plans strategic review, including possible sale, after drug trial failure
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH
Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term